Better Data Tracking Could Hold Key To Indication-Based Pricing Progress
Indication-based pricing could become a reality with better infrastructure to track utilization data.
You may also be interested in...
Different prices for different medical conditions treated by the same drug and tying drug prices to the benefits they deliver are some of the recommendations made by a cross-sector expert panel to improve patient access to innovative cancer medicines.
The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.
New medicines under evaluation at the European Medicines Agency.